1DU CLOS TW.Function of C-reactive protein[J].Ann Med,2000,32:274-278.
2Neeuhaus O,Stasser-Fuchs S,FazeRas F,et al.Sta-tins as immunmodulators.Comparision With inter-feron -B16 in MS[J].Neurology,2002,59:990-997.
3Romano M,Diomede L,Sironi M,et al.Inhibition of Monocyte chemotactic protein-1 synthesis by sta-tins[J].Lab Invest,2000,80:1095-1100.
4Laufs U,Lafata VL,Plutzky J,et al.Uprequlation of endothelial nitric oxide synthase by HMG-CoA re-ductase inhiditors[J].Circulation,1998,97:129-135.
5Wagner AH,Kohler T,Uckschloss U,et al.Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inihbitors through attenuation of endothelial superoxide anion formation[J].Ar-terioscler Thromb Vasc Biol,2000,20:61-69.
6Mraiche F,Cena J,Das D,et al.Effects of statins on vascular function of endothelin-1[J].Br J Pharmacol,2005,144:715-726.
7VAN DER WAL AC,BACKER AE.Atheroscle-rotic plaque rupture pathologic basis of plaque sta-bility and instability[J].Cardiovasc Res,1999,41:334 -334.
8RIDKER PM.High-sensitivity C-reactive protein:potential adjunct for global risk assessmentin the primary prevention of cardiovascular disease[J].Circulation,2001,103:1813-1818.
5Joyner CD, Flather M. Statistical Versus clinical significance of the cure study in acute coronary syndromes[J]. J Am Coll Cardiol ,2002,40(2) :218-221.
